Benefits
Gut microbiota and bile acid metabolism in healthy adults
In an 8-week placebo-controlled trial in 30 healthy adults, 24 mg a day of xanthohumol did not change overall gut bacteria composition. It shifted some individual bacteria and lowered microbial bile acid metabolism only in people with certain gut types, and absorption varied widely. Whether these changes matter for gut comfort or health is not known.
Gut bacteria, bile acids and tolerability in a patient trial
In a small 8-week placebo-controlled trial in 20 adults with active Crohn's disease, 24 mg a day was well tolerated. Disease activity scores fell in both groups with no significant difference from placebo, and gut bacteria did not change. Links between bile acids, IL-10 and symptom scores were exploratory. This is research in patients and not a treatment for any bowel disease.
Inflammatory response of white blood cells after a single dose
In two small placebo-controlled crossover studies (14 healthy adults and 9 healthy women), white blood cells taken 1 hour after a single 0.125 mg dose were challenged in the lab with bacterial components. In the women, release of IL-1 beta and IL-6 was lower than after placebo; in the larger study the difference from placebo was not significant. These are one-dose lab tests on cells, not health outcomes.
Protection of white blood cell DNA from oxidative damage
In a crossover trial in 22 people drinking 12 mg of xanthohumol a day, oxidized DNA in white blood cells and urinary markers of oxidative DNA damage fell, and a follow-up with pure xanthohumol in 10 people agreed. A related study found cells resisted lab-induced DNA damage from food-borne chemicals. These are lab markers from one research group, not health outcomes.
Metabolic markers, body weight and energy expenditure in human trials
Human data on metabolism are thin. In the DNA trial, blood lipids and glucose did not change, and a single 172 mg micellar dose did not change resting energy expenditure, blood pressure or heart rate in 16 healthy women. In the Crohn's safety trial, BMI and the liver enzyme GGT favored xanthohumol as secondary results that need confirmation.
Brain and blood sugar effects seen in animal research
In mice fed a high-fat diet, xanthohumol improved glucose tolerance and reduced deficits in learning and memory, and a review found effects on body weight, lipids and fatty liver only in cell and animal studies, with no published human trials in this area. No human trial of xanthohumol has measured memory or thinking, so these effects remain preclinical.
Mechanism of action
Low absorption and rapid conjugation
After swallowing, xanthohumol is absorbed in two phases, with blood peaks at about 1 hour and 4 to 5 hours, and a half-life of about 18 to 20 hours, and almost all of it circulates as glucuronide and sulfate conjugates; free xanthohumol is 1% or less of the total. Micellar forms and protein-rich capsules are used to raise blood levels.
Dampening of immune cell signaling
In lab cells engineered to carry the TLR2 or TLR4 receptors, which white blood cells use to sense bacterial components, xanthohumol blunted receptor activation, and adding the co-receptor CD14 weakened this effect. In the two human crossover studies, TLR2 and TLR4 protein levels in white blood cells did not change. Whether this matters for health is not known.
Detoxifying enzymes and oxidative DNA damage
In human intervention studies, xanthohumol intake raised the detoxifying enzyme alpha-GST by about 43% and reduced oxidized DNA bases in white blood cells. These are biochemical markers measured in small groups.
Interaction with gut bacteria and conversion products
Gut bacteria metabolize xanthohumol, and in a healthy-adult trial it reduced microbial bile acid metabolism in some gut types. Xanthohumol can form isoxanthohumol, which some people's gut bacteria convert to the estrogen-like 8-prenylnaringenin; in a dosing study 8-prenylnaringenin was undetectable in most participants.
Clinical trials
Triple-masked, randomized, placebo-controlled phase I trial of 24 mg/day 99.8% pure xanthohumol in a rice protein capsule, with blood tests, vital signs and adverse event interviews every 2 weeks (Langley et al. 2021, Mol Nutr Food Res)
30 healthy adults; 27 completed.
No clinically relevant differences from placebo in blood chemistry, blood counts, body weight, vital signs or quality of life. No serious adverse events and no withdrawals for adverse events. All adverse events were mild or moderate, with 58 logged in the xanthohumol group and 42 in the placebo group. The trial tested safety, not benefits.
Triple-masked, randomized, placebo-controlled phase 2 trial with safety as the primary outcome and disease activity (CDAI) as a secondary measure (Bradley et al. 2026, Mol Nutr Food Res)
20 adults with active Crohn's disease, 8 weeks.
Xanthohumol was well tolerated, with adherence above 95% and no attributable serious adverse events. Disease activity scores fell in both groups, with no significant difference between xanthohumol and placebo. Small secondary differences in BMI and the liver enzyme GGT favored xanthohumol. Moderate adverse events were more frequent with xanthohumol at week 6 (9 vs 1), three of them in one participant having a flare.
Randomized crossover trial of single 86 mg and 172 mg doses of native or micellar xanthohumol, plus a placebo-controlled crossover on resting energy expenditure; funded by the maker of the micellar form (Brehmer-Henkel et al. 2026, Mol Nutr Food Res)
12 healthy adults aged 20 to 30 (absorption trial); 16 healthy women (energy expenditure trial).
The micellar form gave about 9 times higher bioavailability than native xanthohumol at both doses, and blood levels rose with dose. A single 172 mg micellar dose did not change resting energy expenditure, blood pressure or heart rate versus placebo. No adverse effects were reported.
Single-dose pharmacokinetic study with blood sampling for 5 days (Legette et al. 2014, Mol Nutr Food Res)
48 healthy adults (24 men, 24 women).
Blood levels rose with dose and showed two peaks, around 1 hour and at 4 to 5 hours. The mean half-life was about 18 to 20 hours at the two higher doses. Most xanthohumol circulated as conjugates of xanthohumol and isoxanthohumol, and 8-prenylnaringenin was undetectable in most participants.
Secondary outcomes of the triple-blind, placebo-controlled phase I trial of 24 mg/day xanthohumol for 8 weeks (Jamieson et al. 2024, Gut Microbes)
30 healthy adults.
Xanthohumol did not significantly change overall gut microbiota composition. Some individual bacteria shifted, and microbial bile acid metabolism fell, but only in people with Prevotella or Ruminococcus gut types. Absorption of xanthohumol metabolites varied widely from person to person.
Single-blind, placebo-controlled crossover; white blood cells taken 1 hour after a drink with 0.125 mg xanthohumol were challenged in the lab with a bacterial wall component (Jung et al. 2022, Eur J Nutr)
14 healthy young men and women.
After placebo, the bacterial challenge raised IL-1 beta, IL-6 and sCD14 release from the cells; after xanthohumol, the rise at 48 hours was no longer significant compared with unchallenged cells. Because of variation between people, IL-1 beta and IL-6 levels did not differ significantly between the xanthohumol and placebo conditions; sCD14 release was lower than after placebo. This is a one-dose lab test on cells, not a measured change in health.
Randomized crossover trial of a beverage providing 12 mg xanthohumol a day, with a follow-up parallel trial using pure xanthohumol (Ferk et al. 2016, Mol Nutr Food Res)
22 participants in the main trial; 10 in the follow-up.
Oxidized DNA bases in white blood cells and urinary markers of oxidative DNA damage fell, and cells were more resistant to lab-induced oxidative damage. Markers of redox status, hormones, blood lipids and glucose did not change. Results are lab markers, not health outcomes.